Spinal Cord Injury Market to Grow at a Substantial Growth Rate During the Forecast Period | Key Companies - Abbvie, Lineage Cell Therapeutics, KAI Pharmaceuticals, Eli Lilly and Company, Ferrer Internacional S.A

The Spinal Cord Injury market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Spinal Cord Injury pipeline products will significantly revolutionize the Spinal Cord Injury market dynamics.  

DelveInsight’s “Spinal Cord Injury Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Spinal Cord Injury, historical and forecasted epidemiology as well as the Spinal Cord Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Spinal Cord Injury market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

To Know in detail about the Spinal Cord Injury market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Spinal Cord Injury Market Insights

Spinal Cord Injury Overview

Spinal cord injury (SCI) is a serious medical condition that causes functional, psychological, and socioeconomic disorders. Long-term, secondary medical complications are common and play an important role in the continuum of care for patients with SCI. Complications are a frequent cause of morbidity and mortality and lead to increased rates of re-hospitalization, loss of employability, and decreased quality of life. The most common cause of spinal cord injury is trauma. Nearly half of the injuries are caused by motor vehicle accidents. Other types of trauma include: falls from height, violence (stabbing or gunshot wounds to the spine), and sporting injuries (diving, football, rugby, equestrian, etc.).

Some of the key facts of the Spinal Cord Injury Market Report: 

  • The Spinal Cord Injury market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

  • The incidence of Spinal Cord Injury in the rest of the world is much lower than in the United States. There are several possible explanations for this. One is the relative absence in most countries of Spinal Cord Injury because of acts of violence

  • The total diagnosed cases of Spinal Cord Injury in the 7MM was estimated to be 722,217 cases in 2021, which is expected to increase in the forecast period (2022-2032)

  • Among the 7MM countries, the United States had the highest diagnosed cases of Spinal Cord Injury followed by Japan, Germany and Italy in 2021. On the other hand, Spain had the lowest diagnosed cases

  • Among the European five countries, Germany had the 80,850 cases which is highest, followed by Italy in 2021. On the other hand, Spain had the lowest diagnosed cases

  • Key Spinal Cord Injury Companies: Athersys, Kancera, AlaMab therapeutics, ReNetX Bio, Histocell, Lineage Cell Therapeutics, Eli Lilly and Company, Ferrer Internacional S.A, AbbVie, Mitsubishi Tanabe Pharma, Pharmazz, Eusol Biotech, Kringle Pharma, and others

  • Key Spinal Cord Injury Therapies: EAllogeneic stem cell therapy, KAND 567, ALMB0166, AXER-204, FAB117-HC, AST-OPC1, Elezanumab, AST-OPC1, MT 3921, PMZ-1620, ES 135, KP-100IT, and others

  • The Spinal Cord Injury epidemiology based on gender analyzed that Males are affected more as compared to females, in case of Spinal Cord Injury

Download the report to understand which factors are driving Spinal Cord Injury epidemiology trends @ Spinal Cord Injury Epidemiological Insights 

Spinal Cord Injury Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Spinal Cord Injury Therapies and Key Companies

  • Elezanumab (ABT-555): Abbvie

  • AST-OPC1: Lineage Cell Therapeutics  

  • Elezanumab: Abbvie

  • KAI-1678: KAI Pharmaceuticals

  • Tadalafil: Eli Lilly and Company

  •  FAB117-HC: Ferrer Internacional S.A

Discover more about therapies set to grab major Spinal Cord Injury market share @ Spinal Cord Injury market forecast 

Spinal Cord Injury Market Drivers

  • New approaches for therapy development

  • Establishment of specialized care centers

  • Absence of approved therapy

  • Rise in Cases

Spinal Cord Injury Market Barriers

  • Hurdles associated with gathering preclinical data

  • Demographic variations in Spinal Cord Injury incidence

  • Ethical concerns associated with stem cell therapies

To know more about Spinal Cord Injury treatment, visit @ Spinal Cord Injury Medications

Comments

Post a Comment

Popular posts from this blog

Beta-thalassemia Market Poised for Significant Growth with Novel Therapies and Rising Prevalence

The Beta-thalassemia market is set to experience remarkable growth in the coming years, driven by the increasing prevalence of the condition and the anticipated launch of innovative therapies. Leading players in the pharmaceutical and biotech industries, including Acceleron Pharma, Agios Pharmaceuticals, Bluebird Bio, and CRISPR Therapeutics, are working diligently to address unmet medical needs and expand treatment options. Download our sample pages @ https://www.delveinsight.com/report-store/beta-thalassemia-market?utm_source=report&utm_medium=promotion&utm_campaign=kpr Market Dynamics and Key Drivers Beta-thalassemia, a hereditary blood disorder caused by mutations in the HBB gene, results in reduced or absent synthesis of beta-globin chains in hemoglobin. This condition affects millions worldwide, with significant prevalence in regions such as the United States, Europe, and Asia. Recent advancements in diagnostics and a heightened focus on genetic counseling have contribute...
Read more

Growth of the Candidemia Market: Drivers, Developments, and Future Outlook (2024-2034)

Candidemia , a bloodstream infection caused by Candida species, poses significant health challenges, particularly among individuals with weakened immune systems. The global candidemia market is projected to experience a compound annual growth rate (CAGR) of 3.16% from 2024 to 2034. citeturn0search0 Market Drivers: Increasing Incidence: The rising number of immunocompromised patients, including those with HIV/AIDS, cancer, or organ transplants, has led to a higher prevalence of candidemia. Advancements in Diagnostics: The adoption of advanced diagnostic techniques, such as molecular assays and biomarker identification, facilitates swift and accurate detection of candidemia, enabling timely intervention and improved patient outcomes. Innovative Therapeutics: The development of novel antifungal medications and immune-based therapies offers enhanced efficacy and reduced adverse effects, contributing to market growth. To know more about candidemia market drivers, visit https://www.delvei...
Read more

Unlocking the Facts: C-Met Mutated Non-Small Cell Lung Cancer Epidemiology, Market Trends, and Leading Players

What is C-Met Mutated Non-small Cell Lung Cancer ? C-Met (also known as MET) is a gene that codes for a protein called the "hepatocyte growth factor receptor" (HGFR) or c-Met receptor. This receptor plays a crucial role in regulating cell growth, survival, migration, and invasion. When the c-Met gene is mutated, it can lead to the abnormal activation of signaling pathways that promote cancer development and progression. How is C-Met Mutated Non-small Cell Lung Cancer epidemiology segmented? C-Met Mutated Non-small Cell Lung Cancer epidemiology is segmented as C-Met Mutated Non-small Cell Lung Cancer Total Incident Cases, Age-specific C-Met Mutated Non-small Cell Lung Cancer cases, Gender-specific C-Met Mutated Non-small Cell Lung Cancer Cases, Stage-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, Type-specific C-Met Mutated Non-small Cell Lung Cancer incident cases, and Total Treated C-Met Mutated Non-small Cell Lung Cancer Cases. What is the C-Met Mutated...
Read more